Skip to main content
. 2018 Mar 19;128(4):1657–1670. doi: 10.1172/JCI94331

Figure 1. Summary plots of gene changes after RTX treatment.

Figure 1

(A) An in vitro rat study was performed using RTX to ablate TRPV1+ neurons, and RNA-Seq was performed on the remaining cells (n = 3). In this experiment, cell death was confirmed independently. Significant genes (MAGIC pipeline) for this experiment are colored accordingly. (B) Data from 3 control and 5 RTX-treated companion dogs (n = 5 DRGs control, n = 14 DRGs RTX) enrolled in a veterinary trial that were treated intrathecally with RTX are plotted similarly (statistics in limma, voom). (C) A single human patient was treated with RTX intrathecally in the lumbar region. Data from C6,7 are plotted against L5. While some differences may exist between these ganglia, there should also be a gradient of RTX action detectable where RTX acts on the TRPV1+ neurons in the lumbar DRGs more strongly than in the cervical segments. (D) A Venn diagram of genes changing 40% or more shows that there is very little overlap between the genes changing in the 3 studies. Only 1 gene, KLHL1 (Kelch-like family member 1), encoding an actin-organizing protein, changes by at least 40% in all 3 data sets.